Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.69
-$0.04(-5.93%)
At close: 4:00 PM EDT
$0.69
-$0.04(-5.93%)
Day’s Range― - ―
52-Week Range$0.50 - $2.00
Previous Close$0.65
Volume24.70K
Average Volume (3M)90.44K
Market Cap
$29.02M
Enterprise Value$69.25
Total Cash (Recent Filing)$30.42M
Total Debt (Recent Filing)$56.61M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 11, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding44,894,756
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.67Price Target Upside141.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$79.64M
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ScalingThe substantial multi-year revenue expansion shows that TELA Bio has commercialized its soft-tissue reconstruction platform and broadened adoption. This establishes a stronger operating base for future growth if execution and product demand stabilize.
Strong Gross-margin ProfileA 72% gross margin provides meaningful contribution potential from each procedure and indicates attractive product economics. Sustained margin strength could help fund commercial investment and eventual operating leverage as revenue scales.
International Market GrowthInternational growth diversifies TELA Bio beyond its domestic sales base and demonstrates demand for its hernia portfolio in established European markets. Continued expansion abroad could broaden the addressable market and reduce reliance on individual U.S. accounts.
Bears Say
Persistent Losses And Cash BurnTELA Bio is not yet funding operations internally, with substantial cash burn alongside deep net and operating losses. Without a durable path to profitability, continued investment and commercialization may require cost cuts or external financing.
Strained Balance SheetHigher leverage and negative equity materially reduce financial flexibility and increase dependence on successful execution. The weaker capital cushion could constrain investment, raise financing risk, and make future funding more dilutive or expensive.
PRS Weakness And Execution RiskThe PRS decline exposes concentration and commercialization risks within the portfolio, while withdrawn guidance signals limited near-term visibility. Longer sales-representative ramps and retraining requirements could delay recovery and prolong operating losses.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.00 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $29.02M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Aug 10, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.15.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,894,756 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went down -15.054%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of operational positives (12% unit growth, strong international performance, LIQUIFIX momentum, improved gross margin and leadership changes) but was dominated by near-term commercial execution issues: a revenue miss (-4% YoY), a sharp PRS revenue decline (~24%), ASP/mix pressure, extended sales ramp timelines, higher interest expense, and withdrawal of full-year guidance. Management outlined concrete remediation steps (leadership upgrades, training programs, market access improvements, cost reductions) and expressed confidence in second-half recovery, but near-term financial and competitive headwinds are material.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$1.67
▲(141.55% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
21.93% Insiders
4.90% Mutual Funds
50.29% Other Institutional Investors
19.46% Public Companies and
Individual Investors